Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or cytotoxic T lymphocyte-associated protein-4 (CTLA-4) have achieved tumor regression in several cancers, such as melanoma, lung cancers, and Hodgkin lymphoma (3, 4). This evidence concerns the gene PDCD1 and lung cancer.